Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Endocr Pract. 2022 Mar 14;28(6):610–614. doi: 10.1016/j.eprac.2022.03.006

Figure 1.

Figure 1

Outcomes at baseline (time 0) and 12 months after initiation of SGLT2 inhibitors in patients with partial lipodystrophy.

A) HbA1c decreased after SGLT2i administration (p=0.028) without change in B) fasting glucose (P=0.62). There was a trend toward decrease in C) C-peptide (P=0.071). D) Both systolic (closed circles) and diastolic (open squares) blood pressure decreased (P=0.011 and 0.013, respectively).